Study of the effects of kisspeptin analogs on the behavior of Danio rerio

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

BACKGROUND: This study aims to analyze the behavioral effects of mammalian Kiss1 kisspeptin analogs, Clone (USA): KS4, KS5, KS6, KS7, KS8, KS9, and Kiss10, on Danio rerio (zebrafish). The peptides have structural variations in the final four amino acids.

MATERIALS AND METHODS: Kisspeptins were dissolved in aquarium water and administered in two doses: 1) 0.01 mg per 1000 ml of water, and 2) 0.1 mg per 1000 ml of water. Phenazepam, an anxiolytic, was also dissolved in water and used in three doses: 1) 0.1 mg per 1000 ml, 2) 0.5 mg per 1000 ml, and 3) 1 mg per 1000 ml. The study compared kisspeptines with anxiolytics using phenazepam as an example in the novelty test. The fish’s response to novelty in the viewing tank was assessed, including diving to the bottom, increased freezing, and decreased movement in the upper half of the tank. Fish residence time in the lower part of the tank after phenazepam administration decreased, especially at a dose of 0.5 and 1 mg/l.

RESULTS: Kisspeptin analogues decreased the indices characterizing the anxious state of the fish. Against the background of Kiss1 kisspeptin analogues, the average fish path length differed significantly in contrast to the effects of phenazepam. KS4 at a dose of 0.1 mg/l showed a 1.4-fold decrease in the number of freezing, in the freezing time, in the trajectory length and 1.5-fold increase in the number of transitions to the upper part of the tank. The dose of 0.01 mg/l decreased the number of freezing, freezing time, and trajectory length by 1,5-3 times. KS5 at a dose of 0.1 mg/l decreased the number of freezing, the freezing time, the trajectory length and the number of transitions to the upper part of the tank by 1.2–1.6 times. The dose of 0.01 mg/l decreased the number of freezing, freezing time, trajectory length by 2.8–3 times. KS6 at a dose of 0.1 mg/l decreased the number of freezing, the freezing time, and the trajectory length by 2–2.5 times. The number of transitions to the upper part of the aquarium increased 2.5 times. The dose of 0.01 mg/ml decreased the number of freezing, freezing time, and trajectory length by 1.7–2.2 times. KS7 at a dose of 0.1 mg/l decreased the number of freezing, freezing time, and trajectory length by 1.3–2 times. The number of movements to the top of the aquarium increased 1.6-fold. The dose of 0.01 mg/l decreased the number of freezing, freezing time, trajectory length by 1.6 times. KS8 at a dose of 0.1 mg/l decreased the number of freezing, the freezing time, and the trajectory length by 1.6 times. The dose of 0.01 mg/l decreased the number of freezing, the freezing time, and the trajectory length by 1.8–2.3 times. KS9 at a dose of 0.1 mg/l decreased the number of freezing, the freezing time, and the trajectory length by 1.2–2 times. The dose of 0.01 mg/l reduced the number of freezing, the freezing time, and the trajectory length by 1.6 times. In Kiss10 at a dose of 0.1 mg/l, there was a 1.4–1.6-fold decrease in the number of freezing, in freezing time, and in trajectory length. There was a 2.7-fold increase in the transitions to the upper part of the aquarium. The dose of 0.01 mg/l decreased the number of freezing, freezing time, and trajectory length by 1.3–1.7 times. We observed a 1.3-fold increase in the number of trajectories. Summarizing the obtained indicators, we came to the conclusion that kisspeptin analogues were not inferior in their effect to the effects obtained after taking the tranquilizer phenazepam. Among mammalian kisspeptin analogues, KS6 at a dose of 0.1 mg/L showed the best performance.

CONCLUSIONS: The study concludes that mammalian Kiss1 kisspeptin analogs and Kiss10 reduce anxiety-phobic reactions to novelty in Danio rerio. The effects of the studied kisspeptin analogs are lower than those of phenazepam. Kisspeptin is involved not only in the modulation of serotonin-dependent behavior in Danio rerio but also in the GABA-ergic system, resembling benzodiazepine-type tranquilizers. The results support the hypothesis that kisspeptin may be involved in the regulation of anxiety-phobic states, likely playing a role in maintaining the emotional aspects of reproductive behavior, such as sexual motivation and arousal.

About the authors

Vladanka A. Goltz

Institute of Experimental Medicine

Author for correspondence.
Email: digitalisobscura@mail.ru

postgraduate student, S.V. Anichkov Department of Neuropharmacology

Russian Federation, Saint Petersburg

Andrey A. Lebedev

Institute of Experimental Medicine

Email: aalebedev-iem@rambler.ru
ORCID iD: 0000-0003-0297-0425
SPIN-code: 4998-5204

Dr. Biol. Sci. (Pharmacology), head of the Laboratory of General Pharmacology of the S.V. Anichkov Department of Neuropharmacology

Russian Federation, Saint Petersburg

Aleksandra A. Blazhenko

Institute of Experimental Medicine

Email: alexandrablazhenko@gmail.com
SPIN-code: 8762-3604

junior research assistant of the S.V. Anichkov Department of Neuropharmacology

Russian Federation, Saint Petersburg

Viktor A. Lebedev

Institute of Experimental Medicine

Email: vitya-lebedev-57@mail.ru
ORCID iD: 0000-0002-1525-8106
SPIN-code: 1878-8392

Cand. Sci. (Biol.), research assistant of the S.V. Anichkov Department of Neuropharmacology

Russian Federation, Saint Petersburg

Sergei V. Kazakov

Institute of Experimental Medicine

Email: svkazakov@mail.ru

postgraduate student of the S.V. Anichkov Department of Neuropharmacology

Russian Federation, Saint Petersburg

Alikber A. Bayramov

Almazov National Medical Research Centre

Email: alekber@mail.ru

leading research associate

Russian Federation, Saint Petersburg

Platon P. Khokhlov

Institute of Experimental Medicine

Email: platonkh@list.ru

Cand. Sci. (Biol.), senior research associate of the S.V. Anichkov Department of Neuropharmacology

Russian Federation, Saint Petersburg

Eugenii R. Bychkov

Institute of Experimental Medicine

Email: bychkov@mail.ru
ORCID iD: 0000-0002-8911-6805
SPIN-code: 9408-0799

Cand. Med. Sci. (Pathophysiology), head of the Laboratory of Chemistry and Pharmacology of Medicinal Compounds of the S.V. Anichkov Department of Neuropharmacology

Russian Federation, Saint Petersburg

Sarng S. Pyurveev

Institute of Experimental Medicine

Email: dr.purveev@gmail.com
ORCID iD: 0000-0002-4467-2269
SPIN-code: 5915-9767

research associate of the S.V. Anichkov Department of Neuropharmacology

Russian Federation, Saint Petersburg

Petr D. Shabanov

Institute of Experimental Medicine

Email: pdshabanov@mail.ru
ORCID iD: 0000-0003-1464-1127
SPIN-code: 8974-7477

Dr. Sci. (Med.), professor and head of the S.V. Anichkov Department of Neuropharmacology

Russian Federation, Saint Petersburg

References

  1. Kotani M, Detheux M, Vandenbogaerde A, et al. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G Protein-coupled receptor GPR54. J Biol Chem. 2001;276(34):631–636. doi: 10.1074/jbc.M104847200
  2. Quillet R, Ayachi S, Bihel F, et al. RF-amide neuropeptides and their receptors in Mammals: Pharmacological properties, drug development and main physiological functions. Pharmacol Ther. 2016;160:84–132. doi: 10.1016/j.pharmthera.2016.02.005
  3. Ohtaki T, Shintani Y, Honda SI, et al. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature. 2001;411(6837):613–617. doi: 10.1038/35079135
  4. Pampillo M, Camuso N, Taylor JE, et al. Regulation of GPR54 signaling by GRK2 and arrestin. Mol Endocrinol. 2009;23(12):2060–2074. doi: 10.1210/me.2009-0013
  5. Szereszewski JM, Pampillo M, Ahow MR, et al. GPR54 regulates ERK1/2 activity and hypothalamic gene expression in a Galpha(q/11) and beta-arrestin-dependent manner. PLoS One. 2010;5(9):129–164. doi: 10.1371/journal.pone.0012964
  6. Lee DK, Nguyen T, O’Neill GP, et al. Discovery of a receptor related to the galanin receptors. FEBS Lett. 1999;446(1):103–107. doi: 10.1016/S0014-5793(99)00009-5
  7. Brailoiu GC, Dun SL, Ohsawa M, et al. KiSS-1 expression and metastin-like immunoreactivity in the rat brain. J Comp Neurol. 2005;481(3):314–329. doi: 10.1002/cne.20350
  8. Overgaard A, Tena-Sempere M, Franceschini I, et al. Comparative analysis of kisspeptin-immunoreactivity reveals genuine differences in the hypothalamic Kiss1 systems between rats and mice. Peptides. 2013;45:85–90. doi: 10.1016/j.peptides.2013.04.013
  9. Higo S, Honda S, Iijima N, Ozawa H. Mapping of kisspeptin receptor mRNA in the whole rat brain and its co-localisation with oxytocin in the paraventricular nucleus. J Neuroendocrinol. 2016;28(4):1–8. doi: 10.1111/jne.12356
  10. Parhar IS, Ogawa S, Sakuma Y. Laser-captured single digoxigenin-labeled neurons of gonadotropin-releasing hormone types reveal a novel G protein-coupled receptor (Gpr54) during maturation in cichlid fish. Endocrinology. 2004;145(8):3613–3618. doi: 10.1210/en.2004-0395
  11. Ogawa S, Parhar IS. Functions of habenula in reproduction and socio reproductive behaviours. Front Neuroendocrinol. 2021;64:100964. doi: 10.1016/j.yfrne.2021.100964
  12. Kitahashi T, Ogawa S, Parhar IS. Cloning and expression of Kiss2 in the zebrafish and medaka. Endocrinology. 2009;150(2):821–831. doi: 10.1210/en.2008-0940
  13. Ogawa S, Parhar IS. Biological significance of kisspeptin-Kiss 1 receptor signaling in the habenula of teleost species. Front Endocrinol. 2018;9:222. doi: 10.3389/fendo.2018.00222
  14. Tang H, Liu Y, Luo D, et al. The Kiss/Kissr systems are dispensable for zebrafish reproduction: Evidence from gene knockout studies. Endocrinology. 2015;156(2):589–599. doi: 10.1210/en.2014-1204
  15. Liu Y, Tang H, Xie R, et al. Genetic evidence for multifactorial control of the reproductive axis in zebrafish. Endocrinology. 2017;158(3):604–611. doi: 10.1210/en.2016-1540
  16. Nakajo M, Kanda S, Karigo T, et al. Evolutionally conserved function of kisspeptin neuronal system is nonreproductive regulation as revealed by nonmammalian study. Endocrinology. 2018;159(1): 163–183. doi: 10.1210/en.2017-00808
  17. Etzion T, Zmora N, Zohar Y, et al. Ectopic over expression of kiss1 may compensate for the loss of Kiss2. Gen Comp Endocrinol. 2020;295:113523. doi: 10.1016/j.ygcen.2020.113523
  18. Ogawa S, Nathan FM, Parhar IS. Habenular kisspeptin modulates fear in the zebrafish. PNAS. 2014;111(10):3841–3846. doi: 10.1073/pnas.1314184111
  19. Adekunbi DA, Li XF, Lass G, et al. Kisspeptin neurones in the posterodorsal medial amygdala modulate sexual partner preference and anxiety in male mice. J Neuroendocrinol. 2018;30(3):e12572. doi: 10.1111/jne.12572.
  20. Katalin E, Ibos ÉB, Zsolt B, et al. Kisspeptin-8 induces anxiety-like behavior and hypolocomotion by activating the HPA Axis and Increasing GABA release in the nucleus accumbens in rats. Biomedicines. 2021;9(2):112. doi: 10.3390/biomedicines9020112
  21. Rao YS, Mott NN, Pak TR. Effects of kisspeptin on parameters of the HPA axis. Endocrine. 2011;39(3):220–228. doi: 10.1007/s12020-011-9439-4
  22. Thomson EL, Patterson M, Murphy KG, et al. Central and peripheral administration of Kisspeptin-10 stimulates the hypothalamic-pituitary-gonadal axis. J Neuroendocrinol. 2004;16(10):850–858. doi: 10.1111/j.1365-2826.2004.01240.x
  23. Csabafi K, Jászberényi M, Bagosi Z, et al. Effects of kisspeptin-13 on the hypothalamic-pituitary-adrenal axis, thermoregulation, anxiety and locomotor activity in rats. Behav Brain Res. 2013;241: 56–61. doi: 10.1016/j.bbr.2012.11.039
  24. Telegdy G, Adamik A. The action of kisspeptin-13 on passive avoidance learning in mice. Involvement of transmitters. Behav Brain Res. 2013;243:300–305. doi: 10.1016/j.bbr.2013.01.016
  25. Insel TR. The challenge of translation in social neuroscience: A review of oxytocin, vasopressin, and affiliative behavior. Neuron. 2010;65(6):768–779. doi: 10.1016/j.neuron.2010.03.005
  26. Bromberg-Martin ES, Matsumoto M, Hikosaka O. Dopamine in motivational control: rewarding, aversive, and alerting. Neuron. 2010;68(5):815–834. doi: 10.1016/j.neuron.2010.11.022
  27. Johnson CS, Hong W, Micevych PE. Posterodorsal medial amygdala regulation of female social behavior: GABA versus glutamate projections. J Neurosci. 2021;41(42):8790–8800. doi: 10.1523/JNEUROSCI.1103-21.2021
  28. Tanaka M, Csabafi K, Telegdy G. Neurotransmissions of antidepressant like effects of Kisspeptin-13. Regul Pept. 2013;180:1–4. doi: 10.1016/j.regpep.2012.08.017
  29. Nathan FM, Ogawa S, Parhar IS. Kisspeptin1 modulates odorant-evoked fear response via two serotonin receptor subtypes (5-HT1A and 5-HT2) in zebrafish. J Neurochem. 2015;133(6):870–878. doi: 10.1111/jnc.13105
  30. Lebedev AA, Blazhenko AA, Goltz VA, et al. Effects of kisspeptin analogues on the behavior of Danio rerio. Reviews on Clinical Pharmacology and Drug Therapy. 2022;20(2):201–210. (In Russ.) doi: 10.17816/RCF202201-210
  31. Shabanov PD, Lebedev VA, Lebedev AA, Bychkov ER. Effect of novelty stress on behavioral responses of Danio rerio and assessment of dose-dependent effects of anxiolytics of benzodiazepine structure with phenazepam as an example. Reviews on Clinical Pharmacology and Drug Therapy. 2017;15(3):57–63. (In Russ.) doi: 10.17816/RCF15357-63
  32. Shabanov PD, Blazhenko AA, Devyashin AS, et al. In search of new brain biomarkers of stress. Research Results in Pharmacology. 2021;7(1):41–46. doi: 10.3897/rrpharmacology.7.63326
  33. Cachat J, Stewart A, Grossman L, et al. Measuring behavioral and endocrine responses to novelty stress in adult Danio rerio. Nature protocols. 2010;5(11):1786–1789. doi: 10.1038/nprot.2010.140
  34. Devyashin AS, Blazhenko AA, Lebedev VA, et al. Assessment of dose-dependent effects of anxiolytics of benzodiazepine structure with diazepam as an example in Danio Rerio. Reviews on Clinical Pharmacology and Drug Therapy. 2020;18(1):43–49. (In Russ.) doi: 10.17816/RCF18143-49
  35. Eresko SO, Airapetov MI, Matveeva NA, et al. Danio rerio as a model object in drug research. Narcology. 2020;19(4):43–48. (In Russ.) doi: 10.25557/1682-8313
  36. Blazhenko AA, Khokhlov PP, Tissen IY, et al. Benzodiazepine tranquilizers abolish the stress-induced increase of the brain ghrelin level in Danio rerio. Reviews on Clinical Pharmacology and Drug Therapy. 2020;18(4):327–332. (In Russ.) doi: 10.17816/RCF184327-332
  37. Lebedev VA, Lebedev AA, Bychkov ER, Shabanov PD. Probability of using the behavioral responses of Danio rerio in assessment of dose-dependent effects of phenazepam. Laboratory Animals for Science. 2018;(1):1–21. (In Russ.) doi: 10.29926/2618723X-2018-01-02
  38. Jakubovski E, Johnson JA, Nasir M, et al. Systematic review and meta-analysis: Dose-response curve of SSRIs and SNRIs in anxiety disorders. Depress Anxiety. 2019;36(3):198–212. doi: 10.1002/da.22854
  39. Padala PR, Padala KP, Majagi A, et al. Selective serotonin reuptake inhibitors-associated apathy syndrome. J Medicine. 2020;99(33): e21497. doi: 10.1097/MD.0000000000021497
  40. Shagiakhmetov FSh. Atypical anti-psychoterritorial election commissions: it is more than similarities or distinctions? Theoretical preconditions. Sovremennaya terapiya v psikhiatrii i nevrologii. 2014;(1):14–22. (In Russ.)
  41. Kaplan HI, Sadock BJ, Grebb JA. Synopsis of psychiatry: behavioral sciences clinical psychiatry. 7th edition. Williams and Wilkins, 1994. 920 p.
  42. Le Doux JE. Evolution of human emotion: A view through fear. Prog Brain Res. 2012;195:431–442. doi: 10.1016/B978-0-444-53860-4.00021-0
  43. McDevitt RA, Hiroi R, Mackenzieet SM, et al. Serotonin 1B autoreceptors originating in the caudal dorsal raphe nucleus reduce expression of fear and depression-like behavior. Biol Psychiatry. 2011;69(8):780–787. doi: 10.1016/j.biopsych.2010.12.029
  44. Herbison AE, de Tassigny X, Doran J, Colledge WH. Distribution and postnatal development of Gpr54 gene expression in mouse brain and gonadotropin-releasing hormone neurons. Endocrinology. 2010;151(1):312–321. doi: 10.1210/en.2009-0552

Copyright (c) 2023 Goltz V.A., Lebedev A.A., Blazhenko A.A., Lebedev V.A., Kazakov S.V., Bayramov A.A., Khokhlov P.P., Bychkov E.R., Pyurveev S.S., Shabanov P.D.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

 


Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».